Carbapenem resistance: overview of the problem and future perspectives

By G. Meletis. Therapeutic Advances in Infectious Disease, 2016

666 citations recorded by the source corpus.

Subfields: Endocrinology, Molecular Medicine, Pharmacology

View Paper: https://www.semanticscholar.org/paper/196ecb54064d5fc72659b596514d6af41a17776e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology

1. L. Poirel
2. P. Nordmann
3. F. Codjoe
4. E. Donkor
5. C. Giske
6. K. Bush
7. J. Pitout
8. A. Carattoli

In Molecular Medicine

1. L. Poirel
2. P. Nordmann
3. F. Codjoe
4. E. Donkor
5. C. Giske
6. T. Strateva
7. K. Bush
8. J. Pitout

In Pharmacology

1. P. Nordmann
2. L. Poirel
3. F. Codjoe
4. E. Donkor
5. T. Strateva

Citations in the corpus

• Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread (2019, background): “pneumoniae, carbapenemases are the main contributing factor to extensive drug resistance, and their recent acquisition and dissemination likely forebodes pan-drug resistance in the near future [21, 22].”
• Carbapenem Resistance: A Review (2017, background): “Vitality of the cell wall is affected when PBPs are repressed, the glycan backbone weakens due to autolysis and eventually the cell is destroyed by osmotic pressure in Gram-negative bacteria [9,18].”
• Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria (2019, background): “to carbapenems in the context of permeability defects [21].”